Alzheimer’s disease: Modeling current and potential targets
Posted
by Andy Smith
on
By the time we are 65, one in ten of us will have contracted Alzheimer’s disease. This rises to fifty ...
News
New Drugs from Old
In this article, published in the autumn 2012 issue of Innovations in Pharmaceutical Technology, Rob Scoffin (Cresset’s CEO) explores the chemical space around existing drug molecules to provide a lower-risk, lower-cost strategy for the discovery of new chemical entities.
Click below to read full article.
Other articles
The importance of understanding protein-protein and protein-ligand interactions in immuno-oncology
Posted by Martin Slater onHistorical context and significance Despite cancer being a disease that has been with us for centuries, it has never been ...
Therapeutic protein degradation by design?
Posted by Martin Slater onThe old problem and the new paradigm Classical small molecule drug paradigms generally involve intervention at a ligand protein binding ...